Bibliography
- Voelter-Mahlknecht S, Ho AD, Mahlknecht U. Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene. Int J Oncol 2006;28:447-56
- Vaziri H, Dessain SK, Eaton EN, et al. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59
- Ford E, Voit R, Liszt G, et al. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006;20:1075-80
- Hisahara S, Chiba S, Matsumoto H, et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci USA 2008;105:15599-604
- Tanno M, Sakamoto J, Miura T, et al. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 2007;282:6823-32
- Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005;2:105-17
- Rosenberg MI, Parkhurst SM. Drosophila Sir2 is required for heterochromatic silencing and by euchromatic hairy/E(Spl) bHLH repressors in segmentation and sex determination. Cell 2002;109:447-58
- North BJ, Marshall BL, Borra MT, et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003;11:437-44
- Onyango P, Celic I, McCaffery JM, et al. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA 2002;99:13653-8
- Alcain FJ, Villalba JM. Sirtuin inhibitors. Expert Opin Ther Pat 2009. In press
- Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13
- Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins - Novel therapeutic targets to treat age-associated diseases. Nature Rev 2008;7:841-53
- Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-2
- Crujeiras AB, Parra D, Goyenechea E, Martínez JA. Sirtuin gene expression in human mononuclear cells is modulated by caloric restriction. Eur J Clin Invest 2008;38:672-8
- Schwer B, Verdin E. Conserved metabolic regulatory functions of Sirtuins. Cell Metab 2008;7:104-12
- Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007;6:505-14
- Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 2005;434:113-8
- Liu Y, Dentin R, Chen D, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008;456:269-74
- Chen D, Bruno J, Easlon E, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008;22:1753-7
- Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β-cells. PLoS Biol 2006;4:210-20
- Smith JS. Human Sir2 and the “silencing” p53 activity. Trends Cell Biol 2002;12:404-6
- Gan L. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease. Drug News Perspect 2007;20:233-9
- Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008;1782:363-9
- Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-6
- Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1 α. J Biol Chem 2005;280:16456-60
- Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007;4:484-94
- Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci 2007;32:555-60
- Barzilai N, Banerjee S, Hawkins M, et al. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 1998;101:1353-61
- Heilbronn LK, De Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 2006;295:1539-48
- Fulco M, Schiltz RL, Iezzi S, et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 2003;12:51-62
- Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999;13:2570-80
- Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001;410:227-30
- Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004;430:686-9
- Boily G, Seifert EL, Bevilacqua L, et al. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS One 2008;3:e1759
- Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6
- Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005;280:17187-95
- Celotti E, Ferrarini R, Zironi R, Conte LS. Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone. J Chromatogr A 1996;730:47-52
- Dourtoglou VG, Makris DM, Bois-Dounas F, Zonas Z. Trans-resveratrol concentration in wines produced in Greece. J Food Comp Anal 1999;12:227-33
- Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-85
- Fan E, Zhang K, Jiang S, et al. Analysis of trans-resveratrol in grapes by micro-high performance liquid chromatography. Anal Sci 2008;24:1019-23
- Beekwilder J, Wolswinkel R, Jonker H, et al. Production of resveratrol in recombinant microorganisms. Appl Environ Microbiol 2006;72:5670-2
- Du Pont (US). WO2006124999; 2006
- Fluxome Sciences AS (DK). WO2006089898; 2006
- Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Patents Cardiovasc. Drug Discov 2007;2:133-8
- Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008;658:68-94
- Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274-83
- Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. Life 2008;60:323-32
- Yang H, Baur JA, Chen A, et al. Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 2007;6:35-43
- Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005;280:17038-45
- Dong F, Ren J. Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism. J Hypertens 2007;25:2138-47
- Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku-70. Mol Cell Biol 2008;28:6384-401
- Csiszar A, Labinskyy N, Podlutsky A, et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008;294:H2721-35
- Univ Chicago (US). WO2008028065; 2008
- PM Vladimirovi RU2302241; 2007
- Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008;3:e2264
- Dsm Ip Assets Bv (NL). WO2007042272; 2007
- Mattson MP, Duan W, Guo Z. Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J Neurochem 2003;84:417-31
- Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169-79
- Harvard College (US). WO2006096780; 2006
- Toppo Frank (US). WO2008013764; 2008
- Zhang Y, McLaughlin R, Goodyer C, Leblanc A. Selective cytotoxicity of intracellular amyloid beta peptide1–42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002;156:519-22
- Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010-3
- Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2 promotes cell survival under stress. Cell 2001;107:137-48
- Wang J, Zhai Q, Chen Y, et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 2005;170:349-55
- Shindler KS, Ventura E, Rex TS, et al. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007;48:3602-9
- Sirtris Pharmaceuticals Inc., WO2006127987; 2006
- Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high calorie diet. Nature 2006;444:337-42
- Liu L, Wang Y, Lam KS, Xu A. Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr Metab Immune Disord Drug Targets 2008;8:89-98
- Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008;374:117-22
- Crunkhorn S, Dearie F, Mantzoros C, et al. Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J Biol Chem 2007;282:15439-50
- Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006;127:1109-22
- Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-68
- Barger JL, Kayo T, Pugh TD, et al. Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp Gerontol 2008;43:859-66
- Sirtris Pharmaceuticals Inc.; WO2007008548; 2007
- Available from: http://www.sirtrispharma.com/pipeline-SRT501.html. [Accesed 20 August 2008]
- Elliot PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Inves Drugs 2008;9:371-8
- Resveratrol Partners LLC (US). WO2005099761; 2005
- DSM IP ASSETS BV (NL). WO2007042272; 2007
- Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302:369-73
- Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical. Chemopreventive efficacy of resveratrol: A Conundrum. Cancer Epidemiol Biomarkers Preven 2003;12:953-7
- Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002;33:387-98
- Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005;49:482-94
- El Mohsen MA, Marks J, Kuhnle G, et al. Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. Br J Nutr 2006;95:51-8
- Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;50:712-16
- Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008;138:1602-8
- Walle T, Hsieh F, Delegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32:1377-82
- Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-52
- Maier-Salamon A, Hagenauer B, Wirth M, et al. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res 2006;23:2107-15
- Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006;11:959-67
- Sirtris Pharmaceuticals. US2007037827; 2007
- Milne JC, Lambert PD, Smith JJ, et al. Activation of the protein deacetylase SIRT1 blunts pro-Inflammatory pathways in vivo. American Diabetes Association's 68th Annual Scientific Sessions. June 2008, San Francisco, CA
- Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008;8:347-58
- Available from: http://www.rsc.org/chemistryworld/News/2007/November/28110703.asp. [Accessed 10 October 2008]